Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2415-2418

  Nishiwaki, Satoshi ^a   Miyamura, Koichi ^a,b   Kato, Chiaki ^c   Terakura, Seitaro ^a   Ohashi, Kazuteru ^d   Sakamaki, Hisashi ^d   Nakao, Shinji ^e   Harigae, Hideo ^b   Kodera, Yoshihisa ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Allogeneic stem cell transplantation; Minimal residual disease; Philadelphia chromosome positive acute lymphoblastic leukaemia; Post transplant imatinib administration

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHIMERA; CHROMOSOME; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955063279     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Gokbuget N and Hoelzer D: Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 6: 114-141, 2002.
2. Abou Mourad YR, Fernandez HF and Kharfan-Dabaja MA: Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Transplant 14: 949-958, 2008.
3. Miyamura K, Tanimoto M, Morishima Y et al: Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 79: 1366-1370, 1992.
4. Miyamura K, Morishima Y, Tanimoto M et al: Prediction of clinical relapse after bone-marrow transplantation by PCR for Philadelphia-positive acute lymphoblastic leukaemia. Lancet 336: 890, 1990. (Pubitemid 20311401)
5. Miyamura K, Takeo T, Kataoka T et al: Detection of minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view. Leuk Lymphoma 11: 181-189, 1993. (Pubitemid 23323846)
6. Carpenter PA, Snyder DS, Flowers ME et al: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109: 2791-2793, 2007.
7. + ALL). Blood 106: 458-463, 2005.
8. World Medical Association: World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 79: 373-374, 2001.
9. Heid CA, Stevens J, Livak KJ et al: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
10. Shimoni A, Leiba M, Schleuning M et al: Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leukemia 23: 190-194, 2009.